Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia: an evidence review group perspective of a NICE single technology appraisal
As part of its single technology appraisal (STA) process, the UK National Institute for Health and Care Excellence (NICE) invited the manufacturer of evolocumab (Amgen) to submit evidence on the clinical and cost effectiveness of evolocumab. The appraisal assessed evolocumab as monotherapy or in com...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Published: |
Springer International Publishing
2017
|
| Online Access: | https://eprints.nottingham.ac.uk/41792/ |